Delivery Order SPE2DB25D3003-SPE2DB25FPXED
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,326.28 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injections. This non-set-aside, competitively awarded contract was issued on September 9, 2025, with an ultimate completion date of September 10, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The firm fixed price delivery order represents a routine pharmaceutical procurement for military...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $7,408.25 on July 28, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors. This non-competitive delivery order, with a completion date of July 29, 2025, will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract utilizes firm fixed pricing and represents a child order under a larger contract vehicle supporting federal medical procurement needs. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,448.81 to AmerisourceBergen Drug Corp for the supply of Mounjaro 15 mg/0.5 ml pen injections. This competitive, non-set-aside contract carries a firm fixed price structure with an ultimate completion date of September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor and...
- The Defense Logistics Agency has awarded a delivery order valued at $2,448.81 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injections in 0.5 ml units. This firm fixed-price delivery order, issued on August 4, 2025, with completion targeted for August 5, 2025, represents a small-value pharmaceutical procurement under DLA's medical supply chain operations. The award was made on a competitive basis with no set-aside designation, reflecting AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,583.88 delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors on April 24, 2025, with completion scheduled for April 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a small-value transaction under AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The product will be delivered to the company's facility in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,613.98 on September 5, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pen injectors. This is a firm fixed price, competitively awarded delivery order with no set-aside designation and a completion date of September 8, 2025. The product will be performed and sourced from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $3,812.90 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on April 22, 2025, with completion scheduled for April 23, 2025. This competitively awarded, firm fixed-price delivery order is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under a child delivery order structure, leveraging the company's broader contracting...
- The Defense Logistics Agency awarded a delivery order valued at $1,826.12 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injectors. This firm fixed price, competitively awarded delivery order was issued on August 28, 2025, with an ultimate completion date of August 29, 2025. The contract represents a non-set-aside procurement, indicating open competition among qualified vendors. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, where the place of...
- The Defense Logistics Agency awarded a $2,431.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen injectables on July 24, 2025, with an ultimate completion date of July 25, 2025. This contract represents a non-set-aside competitive award for pharmaceutical supply to federal healthcare systems. The award was performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters and a major hub for...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,720.90 on July 28, 2025, for the supply of Mounjaro 5 mg/0.5 mL pen injections. This is a firm fixed price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 29, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- SPE2DB25D3003Indefinite Delivery Contract
- SPE2DB25D3003-SPE2DB25FPXEDDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,647.49 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 ml pen injections. This competitively awarded, firm fixed-price contract was executed on September 15, 2025, with an ultimate completion date of September 16, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under a larger contracting vehicle supporting federal pharmaceutical procurement requirements. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor, AmerisourceBergen serves as a critical vendor for military and veteran healthcare systems, supplying an extensive portfolio of brand-name and generic medications, specialty pharmaceuticals, and medical supplies across multiple therapeutic domains. The company's prime IDC with DLA enables flexible fulfillment of pharmaceutical needs across federal healthcare programs, including the Defense Health Agency and U.S. Coast Guard, supporting military healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 9/15/25 |